



cdisc® 2026 Europe Interchange

THE FUTURE IS CONNECTED: STANDARDS AND AI POWERING DIGITAL TRANSFORMATION



MILAN, ITALY | MAIN CONFERENCE: 20-21 MAY | TRAININGS & WORKSHOPS: 18, 19, & 22 MAY

Managing Multiple Screenings: How ADaM.ADPL Enhances Traceability and Analysis Integrity

Rebecca Moretti, Principal Statistical Programmer, Chiesi Farmaceutici S.p.A.
Sebastiaan Van De Vijver, Biostatistical Analyst, SGS Pharma – Clinical Research

Speakers



Rebecca Moretti
Principal Statistical Programmer
Chiesi Farmaceutici S.p.A.



Sebastiaan Van De Vijver
Biostatistical Analyst
SGS Pharma – Clinical Research

Disclaimer and Disclosures

- *The views and opinions expressed in this presentation are those of Chiesi and SGS.*
- *The authors have no real or apparent conflicts of interest to report.*



Agenda

- Illustrating the issue
- Solution for SDTM
- Solution for ADaM
- Conclusion



Agenda


- Illustrating the issue
- Solution for SDTM
- Solution for ADaM
- Conclusion



Multiple screening: Illustrating the issue

Outline

- Subjects being screened more than once
- Capturing all information transparently




Possible scenarios

- Multiple **screenings**

- Case A: Without randomization
- Case B: With randomization

- Multiple **randomizations**

- Case C: Without treatment
- Case D: With ≥ 1 treatment



Agenda

- Illustrating the issue
- **Solution for SDTM**
- Solution for ADaM
- Conclusion



Multiple screening: SDTM Solution


SDTM Implementation

- **Select primary** screening/randomization:

A. First screening



B. Screening with randomization



C. First randomization




D. Randomization with ≥ 1 treatment



SDTM Implementation

How SDTM separates participations while keeping everything traceable




- Tracking in other datasets using subject identifier:
 - USUBJID: same across all records
 - SUBJID: unique per screening/randomization
 - added to all subject-level domains

SDTM examples

- Case A (*multiple screenings, no randomization*):


DOMAIN	USUBJID	SUBJID	RFICDTC	RFSTDTC	RFPENDTC
DM	AA1_276101	276101	2022-01-12		2022-01-17
XM	AA1_276101	276103	2022-01-25		2022-01-30

DOMAIN	USUBJID	SUBJID	VISIT	VSDTC
VS	AA1_276101	276101	SCREENING	2022-01-13
VS	AA1_276101	276103	SCREENING	2022-01-25



SDTM examples

- Case B (*multiple screenings with randomization*):



DOMAIN	USUBJID	SUBJID	RFICDTC	RFSTDTC	RFPENDTC
XM	AA1_276402	276401	2022-01-12		2022-01-17
DM	AA1_276402	276402	2022-01-25	2022-02-10	

DOMAIN	USUBJID	SUBJID	DSDECOD	DSSTDTC
DS	AA1_276402	276401	SCREEN FAILURE	2022-01-17
DS	AA1_276402	276402	RANDOMIZED	2022-02-10


DOMAIN	USUBJID	SUBJID	VISIT	VSDTC
VS	AA1_276402	276401	SCREENING	2022-01-12
VS	AA1_276402	276402	SCREENING	2022-01-25

USUBJID uses the **Primary SUBJID**, not the first SUBJID by IC order.



SDTM examples

- Case C (multiple randomizations, no treatment):




DOMAIN	USUBJID	SUBJID	RFICDTC	RFSTDTC
DM	AA1_276305	276305	2022-01-25	
XM	AA1_276305	276310	2022-02-09	

DOMAIN	USUBJID	SUBJID	DSDECOD	DSSTDTC
DS	AA1_276305	276305	RANDOMIZED	2022-01-29
DS	AA1_276305	276310	RANDOMIZED	2022-02-26

DOMAIN	USUBJID	SUBJID	VISIT	VSDTC
VS	AA1_276305	276305	SCREENING	2022-01-25
VS	AA1_276305	276310	SCREENING	2022-02-09

SDTM examples


- Case D (*multiple randomizations with treatment*):



DOMAIN	USUBJID	SUBJID	RFICDTC	RFSTDTC	RFPENDTC
XM	AA1_276807	276508	2022-02-09		2022-02-27
DM	AA1_276807	276807	2022-03-25	2022-04-01	2022-12-11

DOMAIN	USUBJID	SUBJID	VISIT	VSDTC
VS	AA1_276807	276508	SCREENING	2022-02-09
VS	AA1_276807	276807	SCREENING	2022-03-25

Impact on SDTM-related Documentation



Inclusion of **XM** domain

Clarification on **demography form**

Section 3. Subject Data Description, 3.1. Overview.
Section 3.4 SDTM Subject domains.

Our Approach vs SDTM IG 4.0

Chiesi/SGS approach (referring FDA TCG)	SDTMIG 4.0 approach
DM domain → only primary participation	DM domain → subject summary
XM domain → all other participations	DC domain → all participations

Separation

Consolidation

Early disambiguation

Late disambiguation (reviewer/SAP)

Reviewer-friendly

More complete but more complex

Agenda

- Illustrating the issue
- Solution for SDTM
- **Solution for ADaM**
- Conclusion



Multiple screening: ADaM Solution

ADaM implementation

- ADSL (Subject-Level Analysis Dataset)
 - Limited to one record per subject
- ADPL (Participation-Level Analysis Dataset)
 - 1 record **per participation** of the subject
 - ADSL-like structure, upstream of ADSL
 - ADSL = Sub-selection of ADPL

ADPL structure

- Subset of ADSL variables + ADPL-specific variables
- Case A-D handling at SDTM level
- Copy selection using SRCDOM

USUBJID	SUBJID	SRCDOM	RFICDTC	RFXSTDTC	...
AA1_276807	276508	XM	2022-02-09		
AA1_276807	276807	DM	2022-03-25	2022-04-01	

...	PRANDFL	PRANDDT	PRANDNO	MRANDFL	PRTRTFL	SLINCLFL
	N			N	N	N
	Y	2022-04-01	1001	N	Y	Y

ADSL

- Selection on ADPL.SLINCLFL
- One record per subject

USUBJID	SUBJID	RFICDTC	RFSTDTC	RFXSTDTC	TRTSDTM	RANDFL	RANDDT	RANDNO
AA1_276807	276807	2022-03-25	2022-04-01	2022-04-01	2022-04-01	Y	2022-04-01	1001


Downstream of ADSL

- SUBJID tracks records at participation level
- Merging of datasets on USUBJID+SUBJID

USUBJID	SUBJID	...
AA1_276807	276807	

Impact on ADaM-related Documentation

- Include **ADPL domain**
- ADSL variables inheritance



Section 3. Subject Issues that Require Special Analysis Rules

Agenda

- Illustrating the issue
- Solution for SDTM
- Solution for ADaM
- **Conclusion**



Multiple screening: Conclusion

Summary

- Problem: Capturing of multiple screening/randomization data
- Solution: SDTM + ADaM
 - **Clear selection rules**
 - Domains **XM** and **ADPL**
 - Full **modularity**
 - Transparency and **traceability**
- Collaboration:
 - Chiesi and SGS
 - DM and STAT departments



References

- FDA TCG v5.6 (Dec 2023) section 4.1.1.2 and 4.1.1.3
- PHUSE - PharmaSUG 2023 - Paper SS-146 ADaM Datasets with Multiple Participations per Subject



Thank You!

SGS

Contact SGS



www.sgs.com/pharma



sgs.com/linkedinpharma



clinicalresearch@sgs.com



Visit us at the SGS booth



Contact Chiesi



<https://www.chiesi.com/>



<https://it.linkedin.com/company/chiesi-group>

